Some patients with major depressive disorder are not responsive to treatment* with standard first choice antidepressant drugs. The intensity of their symptoms may have diminished, but they still persist. Characteristically, these patients have failed to respond to more than one conventional antidepressant medication (and perhaps they’ve even failed to respond to combinations of those medications). In these treatment-resistant* cases
- consider prescribing Marplan as an alternative to conventional medications1
- because Marplan works differently than other treatments for major depressive disorder2
Marplan® (isocarboxazid) Tablets harness MAO Inhibitor power to effectively manage the symptoms of major depressive disorder.5
Rediscover Marplan’s efficacy in major depressive disorder in the management of your treatment resistant patients.
Marplan should not be administered in combination with any of the following: MAO inhibitors or dibenzazepine derivatives; sympathomimetrics (including amphetamines); some central nervous system depressants (including narcotics and alcohol); antihypertensive, diuretic, antihistaminic, sedative or anesthetic drugs, bupropion HCL, buspirone HCL, dextromethorphan, cheese or foods with a high tyramine content; or excessive quantities of caffeine. Marplan should not be administered to any patient with a confirmed or suspected cerebrovascular defect or to any patient with cardiovascular disease, hypertension, or history of headache.
*Treatment failure with first-line antidepressants.
†Based upon DSM-V, depression is now referred to as major depressive disorder.
Please click here to review the Marplan references.